The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19.
The regulatory authority had granted the EUA to malarial drugs to be used in hospitalized COVID-19 patients only when a clinical trial was unavailable, or participation in a clinical trial was not feasible.
The agency announced that the drugs have failed to meet the criteria required to be put under EUA. Moreover, ongoing research has revealed that the boxed warnings and side effects such as cardiac arrest and stroke that came along with the use of drugs outweigh the benefits the drugs have to offer.
Hydroxychloroquine ...
